Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Rosacea

Interventions

DRUG: Brimonidine
DRUG: placebo

Sponsor

Actavis Inc.

Collaborators

[object Object]